New Search

If you are not happy with the results below please do another search

2034 search results for:

51

Sperm’s secret switch: Scientists unlock the mystery of motility

Researchers at Stockholm University have unveiled the hidden intricacies of how sperm go from passive bystanders to dynamic swimmers. This transformation is a pivotal step in the journey to fertilization, and it hinges on the activation of a unique ion transporter. Their research is published in the journal Nature [1].

55

Emmes acquires VaxTRIALS

Rockville, Maryland, US-based Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, has acquired VaxTRIALS. Headquartered in Panama City, Panama, VaxTRIALS’ 160+ staff members manage and monitor vaccine clinical trial activities throughout Latin America.

57

SpliceBio collaborates with Spark Therapeutics to develop a gene therapy targeting an undisclosed inherited retinal disease

SpliceBio, a Barcelona, Spain-based genetic medicines company harnessing protein splicing to develop the next generation of gene therapies, has signed an exclusive collaboration and licensing agreement with Philadelphia, Pennsylvania-based Spark Therapeutics to utilize SpliceBio’s proprietary protein splicing platform to develop a gene therapy for an undisclosed inherited retinal disease.

58

Gilead and Assembly Biosciences partner to develop next-gen therapeutics

Gilead Sciences has entered into a 12-year partnership with Assembly Biosciences, a biotechnology company developing antiviral therapeutics targeting serious viral diseases. The partnership, announced 17 October, aims to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio’s established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D […]

59

Mogrify raises $46m to advance reprogramming therapies

Mogrify, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, has closed an additional US$10 million of its Series A financing, bringing the total raised to $46 million in this round. The funding will support further advancement of Mogrify’s pipeline of in vivo reprogramming therapies through pre-clinical […]

60

Yamaha Motor sets up new company to better analyse antibodies in blood

Yamaha Motor Co., Ltd. has established Tuning Fork Bio Inc. in Delaware, USA, which will analyze the antibodies in blood to better visualize people’s health conditions through its antibody profiling business. The main target markets for this new company are the U.S. and Japan.